From Seasonal to Food Allergies: The Next Frontier for Immunotherapy

When most people think of allergy treatment, they picture seasonal sneezing — runny noses in spring, itchy eyes in fall. But for the 32 million Americans living with food allergies, the stakes are far higher. A single bite of the wrong thing can mean a trip to the emergency room — or worse.

For years, the standard advice was simple: avoid the food. Carry an EpiPen. Hope for the best. But a new generation of sublingual immunotherapy is changing that equation entirely — offering a path to desensitization that works from home, without the risks of traditional oral immunotherapy.

The Food Allergy Crisis by the Numbers

Food allergies have been rising sharply for two decades. Between 1997 and 2011, food allergies in children increased by 50%. Today, roughly 8% of children and 10% of adults in the U.S. have at least one food allergy. Peanut allergy alone affects about 1 in 50 children — triple the rate from the early 2000s.

The economic burden is staggering too. Families with food allergies spend an estimated $25 billion annually on medical care, special foods, and lost productivity. The psychological toll — constant vigilance, anxiety at restaurants, fear at school — is harder to quantify but equally real.

How Immunotherapy Crossed Over

Allergen immunotherapy has been treating environmental allergies — pollen, dust mites, mold, pet dander — for over a century. The principle is straightforward: expose the immune system to gradually increasing amounts of an allergen, and it eventually learns to tolerate it. For seasonal allergies, the track record is excellent. Both shots and sublingual drops produce long-term relief in the majority of patients.

Applying this same principle to food allergens took longer. The challenge is that food allergy reactions tend to be more severe and less predictable than environmental reactions. Early attempts at oral immunotherapy (OIT) — swallowing small amounts of the food protein — showed promise but came with significant side effects. Up to 20% of OIT patients experience reactions requiring treatment, and about 10% drop out due to gastrointestinal symptoms.

The Sublingual Advantage

Sublingual immunotherapy (SLIT) takes a different approach. Instead of swallowing the allergen, patients hold drops containing micro-doses under the tongue. The allergen is absorbed through the mucous membranes — an area rich in immune cells called dendritic cells that are particularly good at promoting tolerance rather than triggering reactions.

The result: far fewer and milder side effects compared to OIT. A 2011 study published in the Journal of Allergy and Clinical Immunology found that peanut SLIT patients could tolerate up to 10 times more peanut protein after treatment — with significantly fewer adverse events than those on oral protocols.

What Foods Can Be Treated?

Sublingual immunotherapy is currently being used to treat a growing list of food allergies. The most established evidence exists for peanut, but clinical data and clinical practice are expanding rapidly.

Currently Treatable with SLIT

Clinics offering sublingual food immunotherapy — including online providers like Curex — now treat peanut, tree nuts (almond, cashew, walnut, pecan, pistachio, hazelnut, macadamia, Brazil nut), milk, egg, wheat, soy, sesame, shellfish, and fish. Each treatment is custom-formulated based on the patient's specific allergen profile and sensitivity level.

For children especially, SLIT offers a gentler entry point. No needles, no forced food consumption, no hours in a clinical observation room. Just daily drops under the tongue, gradually building tolerance over months and years.

Environmental + Food: The Full Picture

One of the most compelling aspects of modern SLIT is that it can address environmental and food allergies simultaneously. A child allergic to pollen, dust mites, and peanuts can receive a single custom formulation that covers all their triggers — something that would require multiple separate treatments with shots or tablets.

This matters because allergic conditions tend to cluster. Children with food allergies are 2–4 times more likely to develop environmental allergies, asthma, or eczema. Treating the immune dysfunction comprehensively — rather than one allergen at a time — may help interrupt this "allergic march" before it progresses.

Drops vs. Oral Immunotherapy: Why the Delivery Method Matters

When most people hear "food allergy immunotherapy," they think of oral immunotherapy (OIT) — the approach where patients eat gradually increasing amounts of the food they're allergic to. OIT has received significant media attention, particularly after the FDA approved Palforzia for peanut allergy in 2020. But the reality of OIT is far more complicated — and for many families, far more difficult — than the headlines suggest.

The Problem with OIT

OIT works by forcing the immune system to tolerate an allergen through repeated oral exposure. The process begins with an "initial escalation day" — a 6–8 hour in-office session where the patient ingests tiny but increasing doses under medical supervision. This is followed by months of daily dosing at home, with regular in-office "updoses" every 1–2 weeks where the amount is increased.

The side effect profile is where OIT gets difficult. Systemic allergic reactions occur in 10–25% of patients during treatment. Gastrointestinal symptoms — nausea, vomiting, abdominal pain, reflux — affect up to 50% of patients and are the leading cause of discontinuation. Eosinophilic esophagitis (EoE), a chronic inflammatory condition of the esophagus, develops in an estimated 2.7–5% of OIT patients. And anaphylaxis — the life-threatening reaction the treatment is supposed to prevent — occurs in roughly 9–12% of patients during the course of OIT itself.

There are also significant lifestyle restrictions during OIT. Patients are typically told to avoid exercise for 2 hours after dosing, as physical activity can trigger reactions. Hot showers, alcohol, and NSAIDs like ibuprofen can also increase reaction risk on dosing days. If a patient gets sick — even a common cold — dosing often needs to be paused and restarted at a lower level. For children, this means parents living in constant vigilance about timing, activity, and illness.

Perhaps most critically: OIT doesn't usually produce true tolerance. Most patients achieve "desensitization" — the ability to tolerate a certain amount of the food while actively dosing — but if they stop eating the allergen regularly, protection fades. This means OIT is often a lifelong daily commitment, not a cure.

Why Sublingual Drops Are Different

Sublingual immunotherapy (SLIT) for food allergies takes a fundamentally different approach. Instead of forcing the gut to tolerate large amounts of allergen, SLIT delivers microdoses under the tongue — where the allergen is absorbed through the oral mucosa and processed by dendritic cells that promote immune tolerance rather than triggering a full allergic cascade.

The safety difference is dramatic. In clinical trials and real-world use, SLIT has shown near-zero rates of anaphylaxis. Systemic reactions are extremely rare. The most common side effect is mild, transient oral itching — which typically resolves within the first few weeks. There are no exercise restrictions, no hot shower warnings, and no EoE risk. Dosing continues normally through minor illnesses.

A 2023 systematic review comparing OIT and SLIT for peanut allergy found that while OIT achieved slightly higher levels of desensitization (patients could tolerate larger amounts of peanut), SLIT had a significantly better safety profile, lower dropout rates, and higher rates of sustained unresponsiveness — meaning patients were more likely to maintain tolerance even after stopping treatment.

For many allergists, this tradeoff favors SLIT — particularly for young children, patients with a history of severe reactions, or families who can't manage the intensive monitoring that OIT requires. Providers like Curex offer sublingual immunotherapy for both environmental and food allergies through a telehealth model, with custom drops formulated for each patient's specific allergen profile and shipped directly to their door.

What the Future Looks Like

Research in food SLIT is accelerating. Multiple Phase 3 trials are underway for peanut, milk, and egg sublingual therapies. The FDA approved Palforzia (an oral peanut product) in 2020, but its side effect profile and requirement for in-office dosing have limited adoption. Many allergists believe SLIT will eventually become the preferred route for food desensitization — combining efficacy with the safety and convenience patients need.

For now, custom-compounded SLIT is available through allergists who prescribe it off-label — a practice supported by decades of safety data and endorsed by allergy organizations worldwide. Online clinics like Curex have made access dramatically easier, connecting patients with board-certified allergists and delivering custom drops nationwide.

The era of "just avoid it" is ending. For millions of families, that's a profound relief.